Haemonetics Corporation (HAE)

Market Cap	4.13B
Revenue (ttm)	1.27B
Net Income (ttm)	126.57M
Shares Out	50.79M
EPS (ttm)	2.46
PE Ratio	33.02
Forward PE	19.31
Dividend	n/a
Ex-Dividend Date	n/a

Volume	828,284
Open	83.32
Previous Close	83.46
Day's Range	80.15 - 83.32
52-Week Range	70.74 - 95.26
Beta	0.36
Analysts	Buy
Price Target	102.50 (+26.17%)
Earnings Date	May 9, 2024

About HAE

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It a...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: May 9, 1991
• Employees: 3,034
• Stock Exchange: NYSE
• Ticker Symbol: HAE

Financial Performance

In 2023, Haemonetics's revenue was $1.17 billion, an increase of 17.67% compared to the previous year's $993.20 million. Earnings were $115.40 million, an increase of 166.05%.

Analyst Forecast

According to 4 analysts, the average rating for HAE stock is "Buy." The 12-month stock price forecast is $102.5, which is an increase of 26.17% from the latest price.

Price Target

$102.5

(26.17% upside)

Analyst Consensus: Buy